Alterity Therapeutics logo

Alterity Therapeutics(ASX) ATH

Market CapA$83.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-99%
5 Year-76%
1 Year-34%
1 Month-25%
A$0.36
-2.74%
-0.01Today
Alterity Therapeutics last closing stock price
MetricPriceDate
Last closeAUD 0.372026-10-08
Alterity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.98%AUD 0.412026-10-01
1 month-24.74%AUD 0.492026-09-08
3 month-42.52%AUD 0.642026-07-10
Year to date-8.75%AUD 0.402025-12-31
1 year-33.64%AUD 0.552025-10-08
3 year+4.29%AUD 0.352023-10-09
5 year-76.45%AUD 1.552021-10-08
Since inception-99.25%AUD 51.002000-03-28

Alterity Therapeutics Financials at a Glance

Market Cap

A$83.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.44M

Net Income (TTM)

-A$35.55M

EPS (TTM)

-A$0.11

P/E Ratio

-3.31

Dividend

A$0.00

Beta (Volatility)

-0.42 (Low)

Price

A$0.36

Volume

334,282

Open

A$0.38

Previous Close

A$0.36

Daily Range

A$0.35 - A$0.38

52-Week Range

A$0.35 - A$0.79

Estimated Earnings Date

Mar 4, 2027

ATH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Alterity Therapeutics Limited, based in Melbourne, Australia, is focused on developing innovative treatments for neurological conditions, including Alzheimer's, Huntington's, and Parkinson's diseases. The company is advancing its primary drug candidate, ATH434, which has successfully completed Phase I clinical trials for Parkinson's disease, alongside PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a trials.

Products and Services
  • ATH434: A drug candidate for Parkinson's disease
  • PBT2: Investigational compound targeting Alzheimer's disease
  • Research and development in neurological therapies
Growth Outlook
  • Strong pipeline with two promising drug candidates in clinical trials
  • Significant market potential in treating neurodegenerative diseases
  • Increased investor interest and funding opportunities for R&D
Financial Highlights
  • Cash and cash equivalents of AUD 37.3 million as of June 2026
  • Trailing twelve months (TTM) revenue of AUD 0, reflecting ongoing R&D focus
  • Current ratio of 14.52, indicating strong liquidity position
Alterity Therapeutics Limited is positioned in the biotechnology sector, focusing on critical neurological conditions that affect millions globally. The company's commitment to research and development is evident in its clinical trials and innovative drug candidates. With a robust cash position, the company is well-equipped to continue its research efforts and potentially bring groundbreaking treatments to market. The strong current ratio suggests a solid liquidity position, allowing for sustained operations and development activities. As the global demand for effective neurological treatments grows, Alterity Therapeutics is strategically placed to capitalize on this expanding market.
AI Generated • Sep 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

David A. Stamler, MD

Website

www.alteritytherapeutics.com

Headquarters

Melbourne, VIC 3000, AU

ATH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-48.25%

Return on Capital

-66.22%

Return on Assets

-50.85%

Earnings Yield

-30.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$83.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

229.15M

Volume

334.28K

Avg. Volume

255.95K

Financials (TTM)

Gross Profit

A$5.20M

Operating Income

-A$42.99M

EBITDA

-A$42.83M

Operating Cash Flow

-A$33.24M

Capital Expenditure

A$22.52M

Free Cash Flow

-A$10.71M

Cash & ST Invst.

A$37.32M

Total Debt

A$193.47K

Alterity Therapeutics Performance Analysis

Alterity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Alterity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-24.2%
Q42025-06-30138.7%
Q22025-12-31-100.0%
Q42026-06-30N/A
Alterity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.286.6%
20242024-06-30AUD -0.26-7.9%
20252025-06-30AUD -0.10-63.7%
20262026-06-30AUD -0.1117.1%
Alterity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.0%
Q42025-06-3050.0%
Q22025-12-31-34.3%
Q42026-06-30-34.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$57.64K

-102.8%

Gross Margin

0.00%

N/A

Market Cap

A$83.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$7.60M

N/A

Employees

11

N/A

Net Income

-A$13.79M

-9.3%

EBITDA

-A$15.31M

-4.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$37.32M

+195.3%

Total Debt

A$193.47K

+21.6%

Accounts Receivable

A$7.70M

+90.5%

Inventory

A$0.00

N/A

Long Term Debt

A$138.29K

+166.4%

Short Term Debt

A$55.18K

-48.5%

Return on Assets

-50.85%

N/A

Return on Invested Capital

-66.30%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$11.90M

-46.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUZ.AXNeurizon Therapeutics Limited
A$0.09+1.66%
ALA.AXArovella Therapeutics Limited
A$0.05+8.33%
NYR.AXNyrada Inc.
A$0.48-2.04%
NSB.AXNeuroScientific Biopharmaceuticals Limited
A$0.06+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$142.52-10.31%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$33.37+4.05%
NOKNokia
$10.14-4.52%

Questions About ATH

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at A$0.36 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between A$0.35 and A$0.79.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of A$193.47K.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported A$37.32M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services